MMJ Research Investment Opportunities in Israel
Even after Dr. Sue Sisley found funding and a research home for her study on marijuana in the treatment of PTSD, she had to move her study to Israel because the strains she needed could not be legally obtained in the United States. For many who have watched this saga, it gave a depressingly new perspective on the intellectual poverty prohibition has created.
Medical marijuana is a legal industry in Israel, estimated to be worth $40 million. It has benefitted greatly from 50 years of research and development at academic institutions like the Hebrew University in Jerusalem. The research has been funded, at least in part, by the National Institutes for Health. The result is a wealth of information about the chemistry of cannabis, clinical uses and more precise dosing methods.
The disorderly state of medical marijuana regulation is a serious handicap to the development of cannabis pharmaceuticals in the U.S., but domestic investors have overseas medical marijuana opportunities now. If and when medical research and development is greenlighted in this country, it will be a boon to American medical marijuana businesses. More important to international cannabis pharmaceutical companies, it will open up an enormous market of patients. New options to treat deadly diseases would be good for patients, too, of course.
Israeli Medical Marijuana Companies to Watch
BreedIT Corp, through its Israeli subsidiary, BreedIT Ltd., seeks to discover, develop and commercialize new cannabis strains for the management of a variety of diseases and conditions. It is the developer of software designed to help breeders modify crops to emphasize specific traits. BreedIT Ltd. has teamed up with Seach Ltd, one of only eight entities licensed to grow and distribute medical cannabis in Israel, to form KanaboSeed.
Cannabics Pharmaceuticals (OTCQB: CNBX)
Cannabics Pharmaceuticals, an Israeli company founded in 2012, also focuses on developing cannabinoid-based medicines. The company’s flagship drug is Cannabics SR, a long acting medical cannabis capsule designed for palliative treatment.
One World Cannabis (OTCQB: OWCP)
One World Cannabis, founded in 2014, is an Israeli company focused on the research and development of cannabis-based pharmaceuticals and treatments for a wide variety of medical issues. The company recently completed a reverse merger with an American company called Dynamic Applications, which allows over the counter trading.
This month OWC Pharmaceutical Research Corp.’s wholly owned subsidiary, One World Cannabis Ltd., signed a collaboration agreement with Sheba Academic Medical Center, the largest hospital in the Middle East. OWC will initiate a study to explore the effect of several combinations of CBD and THC in treating multiple myeloma.
Syqe Medical has developed a hand-held inhaler that vaporizes granules of cannabis as small as 1 milligram, giving patients and doctors more control over their dosage. The inhaler has also attracted buzz because it is produced through 3D computer printing. The inhaler is currently used in hospitals and it is expected to be available for home use in 2015.
Tikun Olam describes itself as the first and largest supplier of medical cannabis in Israel, and has received recent CNBC news coverage for its work in the treatment of pediatric cancers. It has a considerable education mission, as well, teaching patients about how to use the drug at its guidance center.
If You Can’t Beat Them …
The reverse merger between One World Cannabis and Dynamic Applications may be harbinger of things to come for medical marijuana investors.
In May 2014, MedReleaf, a Canadian medical marijuana producer, entered into a partnership with Tikun Olam, for a strain of cannabis that benefits epileptic children. Tikun Olan, as a producer with a long history is a particularly rich source of data. PhytoTech Medical, an Australian medical cannabis company is similarly involved in a deal with Yissum, the technology transfer arm of Jerusalem’s Hebrew University, to develop precisely dosed pills for the mainstream pharmaceutical market.
In the future, when American pharmaceutical companies can participate more fully in the marketplace, Israeli companies may be particularly valuable collaborators and partners. We have the market; they’ve had the time and support to develop the expertise.